Akebia upgraded to hold after earnings beat
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Akebia Therapeutics (NASDAQ:AKBA) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. Despite mixed analyst sentiment, the consensus target price for AKBA is $3.90, and the company recently exceeded its quarterly earnings and revenue expectations. Institutional investors have also shown increased interest, modifying their holdings in the biopharmaceutical company.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.